ISRG

Intuitive Surgical, Inc. (ISRG) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates in one reportable segment, managing its business on a consolidated basis. As of March 31, 2026, the company had 354.2 million shares of common stock outstanding.

Key Financial Metrics

Note: The company maintains a debt-free balance sheet. Cash and investments decreased primarily due to stock repurchases and business acquisitions.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 23% year-over-year, driven by a 23% increase in instruments and accessories revenue and a 24% increase in systems revenue.
• Procedure Volume: da Vinci procedures grew 16% to approximately 847,000. Ion procedures grew 39% to approximately 42,700.
• System Placements: Total da Vinci system placements increased 17% to 431 units (including 232 da Vinci 5 systems). Ion system placements increased 6% to 52 units.
• Acquisition: On March 1, 2026, the company acquired the da Vinci and Ion distribution businesses of ab'medica, Abex, and Excelencia Robótica for approximately $533.1 million in cash, assuming direct distribution in Italy, Spain, and Portugal.
• Stock Repurchases: The company repurchased 2.3 million shares for $1.13 billion during the quarter.
• Tax Impact: Effective tax rate was 12.2% in Q1 2026 compared to a benefit of (5.3)% in Q1 2025, largely due to fluctuations in excess tax benefits from employee equity plans.

Guidance, Outlook, and Risks

Management Commentary: Management highlighted strong growth in U.S. general surgery and OUS procedures. The company continues to invest in R&D ($361.9 million) and expects depreciation and intangible amortization to increase in the remainder of 2026 due to recent capital expenditures and the Q1 acquisition.

Risks and Contingencies:

• Tariffs and Trade: The company faces uncertainty regarding U.S. tariffs and trade barriers. Tariffs recognized in cost of revenue were approximately $28 million in Q1 2026. Recent Supreme Court rulings on IEEPA tariffs and new Section 122 tariffs create ongoing volatility.
• Legal Proceedings: Significant antitrust litigation continues, including the appeal of the SIS antitrust case (oral argument scheduled for June 2026) and the "In Re: da Vinci Surgical Robot Antitrust Litigation" class action (class certified, no trial date set). Product liability lawsuits remain pending.
• China Market: System demand in China has been adversely affected by competition from domestic manufacturers and a government campaign on systematic governance, leading to delayed or canceled tenders.
• Supply Chain: Risks include potential disruptions from geopolitical conflicts, semiconductor shortages, and reliance on sole-sourced suppliers.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline for integrating the new European distribution businesses and the impact on operating margins.
• Tariff Exposure: Monitor the final impact of the new 10% Section 122 tariffs and the refund process for previous IEEPA tariffs on cost of revenue.
• China Dynamics: Assess the long-term impact of the Chinese government's governance campaign and domestic competition on system placements and procedure growth in the region.
• Legal Outcomes: Track the status of the SIS antitrust appeal and the class action antitrust litigation for potential financial exposure.
• da Vinci 5 Adoption: Confirm the rate of trade-ins of older systems for the da Vinci 5 and the resulting impact on average selling price (ASP) and recurring revenue.